The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

ABSTRACT:

Background

Salsalate, a nonacetylated prodrug of salicylate, has been shown to decrease blood glucose concentration in small studies.

Objective

To compare the efficacy and safety of salsalate at different doses in patients with type 2 diabetes.

Design

Parallel randomized trial with computer-generated randomization and centralized allocation. Patients and investigators, including those assessing outcomes and performing analyses, were masked to group assignment. (ClinicalTrials.gov registration number: NCT00392678)

Setting

3 private practices and 14 universities in the United States.

Patients

Persons aged 18 to 75 years with fasting plasma glucose concentrations of 12.5 mmol/L or less (< or = 225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% tre

SUBMITTER: Goldfine AB 

PROVIDER: S-EPMC3138470 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature